Clinical Trial

An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease

Name: An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease — clinical trial record (NCT07298590)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

A single arm, open-label pilot study is designed to determine the safety and effectiveness of CD19/BCMA CAR NK cells (KN5601) in patients with IgG4 related diseases.

Trial Details

NCT Number	NCT07298590
Lead Sponsor	Changhai Hospital
Conditions	IgG4 Related Disease
Enrollment	18 participants
Start Date	2025-12-30
Primary Completion	2028-06-26 (estimated)
Study Completion	2028-12-26 (estimated)
Updated on ClinicalTrials.gov	2025-12-23